Kawakami K, Takahashi A, Yoshimoto T
Division of Neurosurgery, Tohoku University School of Medicine, Sendai, Japan.
No To Shinkei. 1990 Feb;42(2):193-201.
Tissue-type plasminogen activator (t-PA) is thought to be a promising fibrinolytic agent because of its high affinity to fibrin without evidence of significant systemic fibrinolysis. The feasibility of t-PA and urokinase (UK) in local fibrinolytic therapy was investigated in a canine common carotid artery thrombus model. After the screening of coagulation-fibrinolytic activities, autologous blood clot was injected into the segment of intimal injured common carotid artery. The fibrinolytic agent was locally applied from the origin of the common carotid artery under temporary flow arrest with a double lumen balloon catheter. T-PA used in this study was produced by the cell culture technique of normal human cells. Its activity was-expressed by AK units (AKU), namely, the fibrinolytic area of the fibrin-agar plate induced by 10 AKU/ml of t-PA solution corresponds to that of 10 IU/ml of UK solution. The doses of t-PA required to produce angiographical recanalization were 600-1,200 AKU/kg (approximately 0.015-0.03 mg/kg) of t-PA, while 24,000 IU/kg was necessary for UK. In these doses, t-PA evoked no adverse effects on the plasma coagulation-fibrinolytic system, while UK produced significant decrease in plasma fibrinogen and alpha-2 plasmin inhibitor levels. Thus, t-PA may be considered to have higher fibrinolytic ability and lower adverse effect on the plasma coagulation-fibrinolytic system than UK. Local fibrinolytic therapy for acute cerebral infarction using t-PA is considered to be a promising intravascular therapeutic procedure with less systemic fibrinolytic complications such as hemorrhagic infarction.
组织型纤溶酶原激活剂(t-PA)因其对纤维蛋白具有高亲和力且无明显全身纤溶证据,被认为是一种很有前景的纤溶药物。在犬类颈总动脉血栓模型中研究了t-PA和尿激酶(UK)进行局部纤溶治疗的可行性。在筛选凝血-纤溶活性后,将自体血凝块注入内膜损伤的颈总动脉段。在使用双腔球囊导管暂时阻断血流的情况下,从颈总动脉起始处局部应用纤溶药物。本研究中使用的t-PA是通过正常人细胞的细胞培养技术生产的。其活性以AK单位(AKU)表示,即10 AKU/ml的t-PA溶液诱导的纤维蛋白-琼脂平板的纤溶面积与10 IU/ml的UK溶液的纤溶面积相当。血管造影再通所需的t-PA剂量为600 - 1200 AKU/kg(约0.015 - 0.03 mg/kg)的t-PA,而UK则需要24000 IU/kg。在这些剂量下,t-PA对血浆凝血-纤溶系统未产生不良影响,而UK则使血浆纤维蛋白原和α-2纤溶酶抑制剂水平显著降低。因此,与UK相比,t-PA可能被认为具有更高的纤溶能力且对血浆凝血-纤溶系统的不良影响更小。使用t-PA对急性脑梗死进行局部纤溶治疗被认为是一种很有前景的血管内治疗方法,其全身纤溶并发症如出血性梗死较少。